Inhibrx Biosciences Inc.
INBX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.2B
Close$
$0.79
99.1% downside
Current Fair Value
99.1% downsideOvervalued by 99.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.20 Billion |
|---|---|
| Enterprise Value | $1.05 Billion |
| Dividend Yield | $0.85 (-) |
| Earnings per Share | $-9.04 |
| Beta | 3.43 |
| Outstanding Shares | 15,585,000 |
Return
| Return on Equity | 618.90% |
|---|---|
| Return on Assets | -70.77% |
| Return on Invested Capital | -78.15% |
Valuation & Multiples
| P/E Ratio | -9.78 |
|---|---|
| PEG | 42.91 |
| Price to Sales | - |
| Price to Book Ratio | -41.77 |
| Enterprise Value to Revenue | 806.17 |
| Enterprise Value to EBIT | -8.52 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-1.20
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-2.28
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 4.22% |
|---|---|
| Total Calls | 300▼ 99.92% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.92%▼ 73.66% |
|---|---|
| Total Invested | $116.89M▼ 86.32% |
| Investors Holding | 24▼ 123.00% |
ESG Score
No data
About Inhibrx Inc
88 employeesInhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the spe...